Logo image of NERV

MINERVA NEUROSCIENCES INC (NERV) Stock Overview

USA - NASDAQ:NERV - US6033802058 - Common Stock

4.7 USD
-0.17 (-3.49%)
Last: 10/24/2025, 8:00:01 PM
4.64 USD
-0.06 (-1.28%)
After Hours: 10/24/2025, 8:00:01 PM

NERV Key Statistics, Chart & Performance

Key Statistics
Market Cap32.85M
Revenue(TTM)N/A
Net Income(TTM)11.23M
Shares6.99M
Float5.44M
52 Week High12.46
52 Week Low1.15
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.03
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO2014-06-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


NERV short term performance overview.The bars show the price performance of NERV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

NERV long term performance overview.The bars show the price performance of NERV in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80

The current stock price of NERV is 4.7 USD. In the past month the price increased by 121.7%. In the past year, price increased by 92.63%.

MINERVA NEUROSCIENCES INC / NERV Daily stock chart

NERV Latest News, Press Relases and Analysis

NERV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.53 402.76B
AMGN AMGEN INC 13.38 157.07B
GILD GILEAD SCIENCES INC 15.63 150.06B
VRTX VERTEX PHARMACEUTICALS INC 24.88 108.04B
REGN REGENERON PHARMACEUTICALS 12.66 61.26B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.75B
ARGX ARGENX SE - ADR 88.74 50.32B
ONC BEONE MEDICINES LTD-ADR 5.02 34.14B
INSM INSMED INC N/A 33.75B
NTRA NATERA INC N/A 26.42B
BNTX BIONTECH SE-ADR N/A 25.40B
BIIB BIOGEN INC 9.36 21.98B

About NERV

Company Profile

NERV logo image Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Company Info

MINERVA NEUROSCIENCES INC

1601 Trapelo Road, Suite 284

Waltham MASSACHUSETTS 02451 US

CEO: Remy Luthringer

Employees: 8

NERV Company Website

NERV Investor Relations

Phone: 16176007373

MINERVA NEUROSCIENCES INC / NERV FAQ

Can you describe the business of MINERVA NEUROSCIENCES INC?

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.


Can you provide the latest stock price for MINERVA NEUROSCIENCES INC?

The current stock price of NERV is 4.7 USD. The price decreased by -3.49% in the last trading session.


What is the dividend status of MINERVA NEUROSCIENCES INC?

NERV does not pay a dividend.


How is the ChartMill rating for MINERVA NEUROSCIENCES INC?

NERV has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What do analysts say about MINERVA NEUROSCIENCES INC (NERV) stock?

6 analysts have analysed NERV and the average price target is 5.1 USD. This implies a price increase of 8.51% is expected in the next year compared to the current price of 4.7.


What is the Price/Earnings (PE) ratio of MINERVA NEUROSCIENCES INC (NERV)?

MINERVA NEUROSCIENCES INC (NERV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.03).


Can you provide the ownership details for NERV stock?

You can find the ownership structure of MINERVA NEUROSCIENCES INC (NERV) on the Ownership tab.


NERV Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to NERV. When comparing the yearly performance of all stocks, NERV is one of the better performing stocks in the market, outperforming 96.4% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NERV Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NERV. NERV may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NERV Financial Highlights

Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -2.03. The EPS increased by 56.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA 36.92%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%60.55%
Sales Q2Q%N/A
EPS 1Y (TTM)56.25%
Revenue 1Y (TTM)N/A

NERV Forecast & Estimates

6 analysts have analysed NERV and the average price target is 5.1 USD. This implies a price increase of 8.51% is expected in the next year compared to the current price of 4.7.


Analysts
Analysts43.33
Price Target5.1 (8.51%)
EPS Next Y17.66%
Revenue Next YearN/A

NERV Ownership

Ownership
Inst Owners27.99%
Ins Owners4.02%
Short Float %0.75%
Short Ratio1.52